



Heart Failure Dashboard

Catholic Health

	Data Through	Current Month	Q3 2026	YTD 2026	2025
<i>Discharge Medications in 4 GDMT Classes</i>					
MRA (spironolactone) (%)	Sep-26	21.7%	25.5%	21.4%	20.6%
SGLT2i (%)	Sep-26	33.3%	37.0%	34.2%	32.7%
RAS Blockers ACEI/ARB/ARNI - <u>any</u> dose (%)	Sep-26	21.7%	25.5%	20.2%	20.2%
Beta Blocker - <u>any</u> dose (%)	Sep-26	45.0%	44.0%	40.3%	37.7%
<i>Patient Type</i>					
HFpEF (EF>50%)	Sep-26	53.3%	50.9%	48.7%	44.5%
<i>LOS</i>					
Average Length of Stay - days	Sep-26	5.1	4.6	5.5	5.8
<i>Readmissions</i>					
All Cause Readmissions (%)	Sep-26	17.5%	15.4%	15.3%	14.6%

"Reference values"

NEJM, Oct 12,ESHF, 11/20-5/22, 2/3 Class III or IV
Referred for heart transplant evaluation

50%

25%

38% ACE/ARB

63% ARNI

95%

Note over 100%
total RAS blockers

Updated: 10/6/2026